Philippe Amouyel

Full Professor

Centre Hospitalier Régional Universitaire de Lille
Country flagFrance
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Alzheimer’s disease (AD) is characterized by a strong genetic predisposition and by an early loss of synaptic connectivity that strongly correlates with cognitive deficit. Some genetic determinants could contribute to synapse frailty toward AD pathology. However, the role of genetic determinants in AD pathogenesis remains poorly understood at the synaptic level. Here, we show that the expression of an isoform of the major AD susceptibility gene BIN1 in the presynaptic compartment results in synaptic loss. Using electrophysiology, we observed an early loss of synaptic transmission upon BIN1 isoform 1 (BIN1iso1) expression in Drosophila retinal photoreceptor neurons. This was not observed for the other human BIN1 isoforms tested, isoform 8 and isoform 9. Structural analysis of photoreceptor neuron synapses shows a strong accumulation of abnormally large vesicles in the presynaptic compartment, reminiscent of this same isoform-induced endosome defects in cell bodies. In addition, the expression of BIN1iso1 in motoneurons of the Drosophila neuromuscular junction alters the morphology of synaptic boutons, with a greater number and a smaller size of synaptic boutons, and the appearance of satellite boutons. As opposed to endosomal defects in cell body, modulating the Rab11 recycling endosome regulator did not prevent BIN1iso1 synaptotoxicity. To test if synaptic deficits are conserved in a mammalian model and to assert a presynaptic vs postsynaptic role for BIN1, we used rat primary neurons cultured in microfluidic devices that restrict gene expression modulation in particular neuron populations. We found a loss of synaptic connectivity only when expressing BIN1iso1 in the presynaptic compartment, which was confirmed by microelectrode array analysis. Together, our results suggest that BIN1 expression in the presynaptic terminal, but not the postsynaptic terminal leads to an isoform-specific, deleterious effect on synaptic integrity. BIN1 synaptotoxicity could contribute to the synapse loss observed early in AD. This supports the idea that genetic determinants could make synapses prone to failure in AD.

Year:

2025

Background Chatbots have demonstrated promising capabilities in medicine, scoring passing grades for board examinations across various specialties. However, their tendency to express high levels of confidence in their responses, even when incorrect, poses a limitation to their utility in clinical settings. Objective The aim of the study is to examine whether token probabilities outperform chatbots’ expressed confidence levels in predicting the accuracy of their responses to medical questions. Methods In total, 9 large language models, comprising both commercial (GPT-3.5, GPT-4, and GPT-4o) and open source (Llama 3.1-8b, Llama 3.1-70b, Phi-3-Mini, Phi-3-Medium, Gemma 2-9b, and Gemma 2-27b), were prompted to respond to a set of 2522 questions from the United States Medical Licensing Examination (MedQA database). Additionally, the models rated their confidence from 0 to 100, and the token probability of each response was extracted. The models’ success rates were measured, and the predictive performances of both expressed confidence and response token probability in predicting response accuracy were evaluated using area under the receiver operating characteristic curves (AUROCs), adapted calibration error, and Brier score. Sensitivity analyses were conducted using additional questions sourced from other databases in English (MedMCQA: n=2797), Chinese (MedQA Mainland China: n=3413 and Taiwan: n=2808), and French (FrMedMCQA: n=1079), different prompting strategies, and temperature settings. Results Overall, mean accuracy ranged from 56.5% (95% CI 54.6‐58.5) for Phi-3-Mini to 89% (95% CI 87.7‐90.2) for GPT-4o. Across the United States Medical Licensing Examination questions, all chatbots consistently expressed high levels of confidence in their responses (ranging from 90, 95% CI 90-90 for Llama 3.1-70b to 100, 95% CI 100-100 for GPT-3.5). However, expressed confidence failed to predict response accuracy (AUROC ranging from 0.52, 95% CI 0.50‐0.53 for Phi-3-Mini to 0.68, 95% CI 0.65‐0.71 for GPT-4o). In contrast, the response token probability consistently outperformed expressed confidence for predicting response accuracy (AUROCs ranging from 0.71, 95% CI 0.69‐0.73 for Phi-3-Mini to 0.87, 95% CI 0.85‐0.89 for GPT-4o; all P <.001). Furthermore, all models demonstrated imperfect calibration, with a general trend toward overconfidence. These findings were consistent in sensitivity analyses. Conclusions Due to the limited capacity of chatbots to accurately evaluate their confidence when responding to medical queries, clinicians and patients should abstain from relying on their self-rated certainty. Instead, token probabilities emerge as a promising and easily accessible alternative for gauging the inner doubts of these models.

Year:

2025

Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.

Year:

2025

We developed a high content screening to investigate how Alzheimer disease (AD) genetic risk factors may impair synaptic mechanisms in rat primary neuronal cultures. Out of the gene targets identified, we found that shRNA-mediated downregulation of Plcg2 in mouse dentate gyrus neurons consistently impaired dendritic morphology and synaptic function. In human neuronal cultures (hNCs), PLCG2 downregulation also impaired synaptic function and was associated with increased levels of Aβ and Tau phosphorylation, potentially via the AKT/GSK3β axis. Very rare PLCG2 loss-of-functon(LoF) variants were associated with a 10-fold increased AD risk. PLCG2 LoF carriers exhibit low mRNA/protein PLCG2/PLCγ2 levels, consistent with nonsense-mediated mRNA decay mechanisms. Restoring PLCγ2 levels in shPLCG2-hNCs fully reversed the disease-related phenotypes. Our findings indicate that the downregulation of PLCγ2 increases the risk of AD by impairing synaptic function and increasing the levels of Aβ and Tau phosphorylation in neurons.

Year:

2024

Bridging Integrator 1 ( BIN1 ) is the second most important Alzheimer’s disease (AD) risk gene, but its physiological roles in neurons and its contribution to brain pathology remain largely elusive. In this work, we show that BIN1 plays a critical role in the regulation of calcium homeostasis, electrical activity, and gene expression of glutamatergic neurons. Using single-cell RNA-sequencing on cerebral organoids generated from isogenic BIN1 wild type (WT), heterozygous (HET) and homozygous knockout (KO) human-induced pluripotent stem cells (hiPSCs), we show that BIN1 is mainly expressed by oligodendrocytes and glutamatergic neurons, like in the human brain. Both BIN1 HET and KO cerebral organoids show specific transcriptional alterations, mainly associated with ion transport and synapses in glutamatergic neurons. We then demonstrate that BIN1 cell-autonomously regulates gene expression in glutamatergic neurons by using a novel protocol to generate pure culture of hiPSC-derived induced neurons (hiNs). Using this system, we also show that BIN1 plays a key role in the regulation of neuronal calcium transients and electrical activity via its interaction with the L-type voltage-gated calcium channel Cav 1.2 . BIN1 KO hiNs show reduced activity-dependent internalization and higher Cav 1.2 expression compared to WT hiNs. Pharmacological blocking of this channel with clinically relevant doses of nifedipine, a calcium channel blocker, partly rescues electrical and gene expression alterations in BIN1 KO glutamatergic neurons. Further, we show that transcriptional alterations in BIN1 KO hiNs that affect biological processes related to calcium homeostasis are also present in glutamatergic neurons of the human brain at late stages of AD pathology. Together, these findings suggest that BIN1 -dependent alterations in neuronal properties could contribute to AD pathophysiology and that treatment with low doses of clinically approved calcium blockers should be considered as an option to slow disease-onset and progression.

Year:

2024

Collaborators (59)

Ruth Frikke-Schmidt

Professor, Chief Physician, MD PhD DMSc

-

DENMARK
View details

Pau Pastor

Institut Català de la Salut

SPAIN
View details

Eloy Rodriguez-Rodríguez

Instituto de Investigación Marqués de Valdecilla

SPAIN
View details

innocenzo rainero

University of Turin

ITALY
View details

Agustín Ruiz Laza

Director of the Biology Core

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Jesper Qvist Thomassen

Senior Scientist

Rigshospitalet

DENMARK
View details

Henne Holstege

Professor

KU Leuven

BELGIUM
View details

Marco Spallazzi

Adjunt professor

University of Parma

ITALY
View details

Benedetta Nacmias

University of Florence

ITALY
View details

Lucilla Parnetti

Professor of Neurology

University of Perugia

ITALY
View details

Caroline Jonson

University of California, San Francisco

UNITED STATES
View details

Jordi Pérez-Tur

Coordinador Adjunto al Área Global Vida

Agencia Estatal Consejo Superior de Investigaciones Científicas

SPAIN
View details

Patrizia Mecocci

Director

Karolinska Institutet

SWEDEN
View details

Caroline Graff

Professor,MD PhD

Karolinska Institutet

SWEDEN
View details

Henna Martiskainen

University of Eastern Finland

FINLAND
View details

Patrik Verstreken

Group Leader, Director and Professor

KU Leuven

BELGIUM
View details

Amy Kit Yu Fu

Research Professor

The Hong Kong University of Science and Technology

HONG KONG
View details

Arvid Rongve

Professor

University of Bergen

NORWAY
View details

Jean-Charles Lambert

Head of research unit

INSERM

FRANCE
View details

Nancy Yuk-Yu Ip

The Morningside Professor of Life Science

The Hong Kong University of Science and Technology

HONG KONG
View details

Katja Scheffler

Associate Professor

Norwegian University of Science and Technology

NORWAY
View details

Julien Chapuis

Université de Lille

FRANCE
View details

Takeshi Ikeuchi

Professor

Brain Research Institute, Niigata University

JAPAN
View details

Geir Selbaek

Professor

University of Oslo

NORWAY
View details

Aarno Palotie

University of Helsinki

FINLAND
View details

Pablo Mir

-

SPAIN
View details

Tormod Fladby

Professor ll of Neurology

University of Oslo

NORWAY
View details

Frank Lafont

Director

CNRS Délégation Nord Pas-de-Calais et Picardie

FRANCE
View details

Srdjan Djurovic

Senior Researcher

University of Oslo

NORWAY
View details

Sami Heikkinen

Research Director

University of Eastern Finland

FINLAND
View details

Najaf Amin

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Wiesje van der Flier

Scientific director

VU medisch centrum

NETHERLANDS
View details

Peter Holmans

Professor of Biostatistics and Genetic Epidemiology

Cardiff University

UNITED KINGDOM
View details

Marcos R. Costa

Lab Head/Professor

Federal University of Rio Grande do Norte

BRAZIL
View details

Dan Rujescu

Head of Clinical Division of General Psychiatry

Medical University of Vienna

AUSTRIA
View details

Alessio Squassina

Dalhousie University

CANADA
View details

Carole Dufouil

Director of research

INSERM

FRANCE
View details

Martin Ingelsson

Specialist

Uppsala University Hospital

SWEDEN
View details

Hilkka Soininen

Kuopio University Hospital

FINLAND
View details

Gael Nicolas

PUPH

University of Rouen

FRANCE
View details

Devrim Kilinc

Institut Pasteur de Lille

FRANCE
View details

Anssi Lipponen

University of Eastern Finland

FINLAND
View details

Claudio Queiroz

Associate Professor

Federal University of Rio Grande do Norte

BRAZIL
View details

Avishek Roy

Karolinska Institutet

SWEDEN
View details

Patrick Kehoe

Academic , Gestetner Professor of Translational Dementia Research

University of Bristol

UNITED KINGDOM
View details

Alfredo Ramirez

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

INGVILD SALTVEDT

Professor

Norwegian University of Science and Technology

NORWAY
View details

Dag Aarsland

Professor and Head of Department

King’s College London

UNITED KINGDOM
View details

Daniela Galimberti

Associate Professor

Università degli Studi di Torino

ITALY
View details

Ole A. Andreassen

Oslo University Hospital

NORWAY
View details

Lucio Tremolizzo

Associate Professor of Neurology

University of Milano-Bicocca

ITALY
View details

Valentina Escott-Price

Professor

Cardiff University

UNITED KINGDOM
View details

Ville Leinonen

Professor

University of Eastern Finland

FINLAND
View details

Rebecca Sims

Senior Research Fellow

Cardiff University

UNITED KINGDOM
View details

Simon Mead

Deputy Director

University College London

UNITED KINGDOM
View details

Barbara Borroni

Docenti di ruolo di IIa fascia

University of Brescia

ITALY
View details

Jose Luis Royo

University of Malaga

SPAIN
View details

Mikko Hiltunen

University of Eastern Finland

FINLAND
View details

Julia TCW

Assistant Professor, Director

Boston University School of Medicine

UNITED STATES
View details